Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment
Back in April, Blackstone announced a massive, multibillion dollar investment in Alnylam Pharmaceuticals, but not all the R&D details were finalized. On Monday, we got a glimpse at how some of those details ended up looking.
The newly-cemented R&D agreement calls for $150 million to be paid to Alnylam for the development of two pipeline products, vutrisiran and ALN-AGT. $70 million will go toward supporting Phase III vutrisiran trials in ATTR amyloidosis-related cardiomyopathy, while the other $80 million will advance Phase II and III studies for ALN-AGT in hypertension therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.